12 results about "Asthma symptoms" patented technology

The invention discloses a bronchial asthma symptom intelligent monitoring method and system based on multi-source data, and relates to the technical field of artificial intelligence, and the method comprises the steps: obtaining multi-mode asthma data after time-space alignment; performing weighted fusion on the western medicine index, the environment index, the tongue condition index and the pulse condition index by using a preset pathogenesis mapping rule to generate an asthma pathology state vector; inputting the asthma pathology state vector into an emergency response channel, analyzing abnormal change of short-term peak flow velocity, synchronously inputting into a chronic evolution channel to track long-term change of tongue condition and pulse condition, and generating emergency response integral and syndrome integral; and superposing the emergency response integral and the syndrome integral on a time axis, and triggering risk assessment when the emergency response integral and the syndrome integral meet the time condition coincidence and the peak flow rate declines to reach an early warning threshold value. According to the method, asthma pathology state vectors are respectively input into an emergency response channel and a chronic evolution channel, so that synchronous monitoring and dynamic modeling of acute attack and chronic disease courses are realized.

The invention belongs to the technical field of traditional Chinese medicine preparations, and particularly relates to an innovative formula and a preparation method of a traditional Chinese medicine preparation for relieving cough and asthma, and the traditional Chinese medicine preparation comprises the following medicinal materials in parts by weight: 10-20 parts of flos farfarae, 10-20 parts of radix asteris, 5-15 parts of ephedra, 5-15 parts of almond, 5-15 parts of scutellaria baicalensis, 5-15 parts of white mulberry root-bark, 5-15 parts of radix stemonae and 3-10 parts of liquorice. Through reasonable compatibility of various traditional Chinese medicines, the traditional Chinese medicine composition acts on the respiratory system in a multi-target manner, can moisten the lung to arrest cough, can release the lung to relieve asthma, can clear heat and reduce phlegm, and has a good treatment effect on cough and asthma caused by various reasons. Animal experiments and clinical preliminary verifications prove that compared with a traditional Chinese medicine preparation for relieving cough and asthma, the preparation disclosed by the invention can more remarkably prolong the cough latency period, reduce the cough frequency, relieve the asthma symptom and improve the lung function, and the links such as reduced pressure concentration and preparation forming in the preparation process are all carried out under strict condition control, so that the traditional Chinese medicine preparation is free of toxic and side effects. The loss and degradation of effective components are reduced, and the stability and consistency of the product quality are ensured.

The application belongs to the technical field of biological medicine, and particularly relates to application of an active component of chamomile in preparation of an asthma treatment preparation. The chamomile active component is prepared by the following method: chamomile is subjected to reflux extraction with ethanol as an extraction solvent to obtain an extract; the extract is purified, eluted with water and ethanol in sequence, and the eluate of ethanol is collected and dried to obtain the chamomile active component. The chamomile active component provided in the application can regulate autophagy and apoptosis through multiple targets, inhibit airway inflammation, and improve immune imbalance, and can not only effectively relieve asthma symptoms, but also reduce airway epithelial damage and inhibit airway remodeling, thereby overcoming the defects of existing drugs, such as large side effects, limited efficacy on severe and hormone-resistant asthma patients, and difficulty in reversing airway damage. The active component is derived from a natural plant, is safe, and has a good application prospect in preparation of asthma treatment drugs.

The invention relates to the technical field of tracheitis treatment, in particular to a spittoon asthma tablet and a preparation method thereof. The tablets for treating asthma caused by excessive phlegm comprise 60-80 parts of radix sophorae flavescentis extract, 5-10 parts of golden cypress fruit oil, 20-30 parts of filler, 1-2 parts of lubricant, 5-10 parts of lily, 2-5 parts of fried almond and 0.5-1 part of liquorice. The sophora flavescens extract, the cortex phellodendri oil and the lily have a synergistic effect, and after the sophora flavescens extract, the cortex phellodendri oil and the lily are combined, cough and asthma such as chronic tracheitis or bronchitis can be remarkably treated, and the effect is remarkable.

The invention provides a budesonide inhalable solution composition and a preparation method thereof. Compared with an existing budesonide suspension preparation, the budesonide inhalable solution composition provided by the invention is stable in property; the budesonide and the terbutaline sulfate contained in the solution composition have excellent delivery performance and pharmacokinetic properties, can be better distributed on the surface of bronchus or lung, and can be quickly dissolved and absorbed, quickly exert efficacy and relieve asthma symptoms. The budesonide inhalable solution composition provided by the invention is simple in preparation method and easy for industrial production.

The invention relates to the technical field of traditional Chinese medicine pharmacy, and particularly discloses a cough and asthma patch and a preparation method thereof. The cough and asthma patch is prepared from active ingredients and a matrix, the active ingredients are prepared from folium eriobotryae, almonds, elaeagnus pungens, actinidia chinensis roots, thyme, polygala japonica, elephantopus scaber, gynura bicolor, veronica didyma, borneol and mentholum, and the matrix is bionic polymeric gel. The preparation method comprises the following steps: S1, preparing the extract; s2, colloid melting: melting the bionic polymer gel; s3, mixing to prepare paste: adding the extract obtained in S1, borneol and mentholum into the molten colloid obtained in S2, and stirring and mixing; and S4, forming. The cough and asthma patch can be used for relieving cough and asthma symptoms caused by asthma and chronic bronchitis, and has the advantages of being rapid in effect taking and lasting in medicine effect; in addition, the preparation method of the cough and asthma patch has the advantages of improving the transfer rate of the active ingredients, the homogeneity of the paste and the low-temperature stability.

The invention relates to an asthma symptom description classification method and system based on multi-task learning. The method comprises the following steps: constructing a multi-task learning module based on shared parameters; specifically, the multi-task learning module comprises a shared task and a plurality of classification tasks, and the shared task generates universal feature vectors for all the classification tasks; the asthma symptom description text is input into a multi-task learning module, and each classification task generates a classification result vector and a loss value; a total classification result vector is generated based on the classification result vector. According to the method, analysis of the same asthma symptom is subjected to multi-dimensional splitting, so that strong association information in the same symptom is effectively utilized, mode information in a classification task can help a model to better learn another task, the flexibility and configurability of a multi-task learning module are improved, and the learning efficiency is improved. Knowledge is migrated from other tasks with rich data through the shared encoder, so that better performance is obtained.

The invention discloses a ginsenoside composition and an application thereof, and particularly relates to an application of the ginsenoside composition in preparation of a medicine for treating asthma. The core of the composition is that the composition comprises the following components in specific parts by weight: 4-8 parts of ginsenoside Rg1 and 1-3 parts of ginsenoside Rb1, and 2-4 parts of total ginsenoside which takes effect together with one of the ginsenoside Rg1 and the ginsenoside Rb1 and is prepared through standardization, and the total content of the Rg1 and the Rb1 in the total ginsenoside is 50-70%. According to the present invention, the known pure saponin product and the standardized total saponin rich in the specific unknown saponin group are combined according to the specific ratio so as to produce the unexpected synergistic effect; pharmacodynamic experiments prove that the composition can significantly improve asthma symptoms and effectively inhibit airway inflammation, mucus hypersecretion and immune imbalance, and the curative effect of the composition is significantly superior to that of a single component or common total saponins. Meanwhile, the product quality is stable and controllable through a specific extraction and purification process.

The invention discloses application of human metapneumovirus in preparation of a medicine for treating asthma, and belongs to the technical field of asthma medicines. The human metapneumovirus is used in the medicine for treating asthma, can relieve airway hyperresponsiveness of an asthma patient, reduce expression of MUC5AC, IL-4 and p-STAT6 proteins of the asthma patient, reduce the total cell number, eosinophilic granulocyte number and neutrophil number in BALF, and can effectively treat asthma and relieve asthma symptoms.

The invention belongs to the technical field of biological medicines, and particularly relates to application of xanthohumol in preparation of a medicine for relieving allergic rhinitis and asthma symptoms. By constructing an animal model and a cell model, results show that xanthohumol can be successfully absorbed and metabolized by a digestive tract to play a biological role, and OVA-induced allergic airway inflammatory response can be remarkably improved. Compared with a disease model group, the xanthohumol can reduce the proportion of inflammatory cells in peripheral blood and BALF of mice and improve the infiltration condition of eosinophilic granulocytes in lung tissues. In addition, xanthohumol can regulate Th cell balance and cell factor release in mouse lung tissue. The oxidative stress state represented by OVA-induced ROS level rise causes the release of dsDNA and the activation of AIM2 inflammasome-related protein to be an important mechanism for mediating allergic airway inflammatory reaction, and the expression can be obviously improved by xanthohumol, so that a potential target and an effective strategy are provided for clinical treatment in the future.

The application provides a compound medicine for relieving cough and asthma in atomization treatment of respiratory system and a preparation and application thereof. The medicine is prepared from white ginkgo, ephedra and other Chinese medicinal materials as main raw materials, and further comprises complex bacteria, an osmotic pressure regulator and a dissolving agent. The complex bacteria are composed of cordyceps sinensis, bamboo lotus and pine olive in a specific mass ratio, the osmotic pressure regulator is glucose and glycerol in a specific ratio, and the dissolving agent can be selected from multiple kinds. The preparation method comprises multiple steps, including unique processes such as extraction of medicinal materials, salt modification and ultrasonic extraction. Through clinical tests, compared with a control group and a placebo group, the compound medicine can significantly improve the lung function related indexes of patients, reduce the inflammatory factor level, and effectively relieve the cough and asthma symptoms through a visual analogue scale method. The medicine can be used for preparing an atomization inhalation medicine for treating bronchial asthma, chronic obstructive pulmonary disease and other respiratory diseases, and has a good application prospect.

The invention discloses application of a target expression inhibitor to preparation of a medicine for preventing and treating asthma. The invention discovers that the expression of OR5W2 in an asthma cell model is significantly up-regulated, the overexpression of OR5W2 can significantly promote the expression of IL-33 and CCL20 in the asthma cell model, and the knock-down of OR5W2 can significantly inhibit the expression of IL-33 and CCL20 in the asthma cell model. Technicians in the field know that IL-33 and CCL20 are key factors for causing a series of asthma symptoms, when a body inhales allergens, airway epithelial cells can secrete chemotactic factors CCL20 to attract mononuclear cells and immature dendritic cells into the lung, meanwhile, IL-33 is secreted to activate the lung dendritic cells and promote Th2-type immune response, and therefore, the lung is prevented from being infected by the lung. A series of asthma symptoms are further caused. Therefore, the OR5W2 expression inhibitor has the prospect of being developed into the medicine for preventing and treating asthma.